Chemours Adds Directors, Updates Executive Pay

Ticker: CC · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1627223

Chemours Co 8-K Filing Summary
FieldDetail
CompanyChemours Co (CC)
Form Type8-K
Filed DateMar 25, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $975,000, $4,355,000
Sentimentneutral

Sentiment: neutral

Topics: governance, board-of-directors, executive-compensation

Related Tickers: CC

TL;DR

Chemours adds 2 new directors to the board, effective March 21st.

AI Summary

On March 22, 2024, The Chemours Company filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company announced the election of two new directors, Ms. Dawn R. Reardon and Mr. David A. Schanzer, to its Board of Directors, effective March 21, 2024. The filing also disclosed updates to the compensatory arrangements for certain officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns routine corporate governance changes like director appointments and executive compensation updates, which typically carry low immediate risk.

Key Players & Entities

  • The Chemours Company (company) — Registrant
  • Dawn R. Reardon (person) — Newly elected director
  • David A. Schanzer (person) — Newly elected director
  • March 21, 2024 (date) — Effective date of director appointments
  • March 22, 2024 (date) — Date of 8-K filing

FAQ

Who are the newly elected directors to The Chemours Company's Board?

Ms. Dawn R. Reardon and Mr. David A. Schanzer were elected as new directors.

When were the new directors' appointments effective?

The appointments of Ms. Dawn R. Reardon and Mr. David A. Schanzer were effective March 21, 2024.

What type of corporate event is reported in this 8-K filing?

This 8-K reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

What is the principal executive office address for The Chemours Company?

The principal executive offices are located at 1007 Market Street, Wilmington, Delaware 19801.

What is the Commission File Number for The Chemours Company?

The Commission File Number for The Chemours Company is 001-36794.

Filing Stats: 831 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-03-25 06:04:04

Key Financial Figures

  • $0.01 — ange on Which Registered Common Stock ($0.01 par value) CC New York Stock Exchan
  • $975,000 — nd consists of an annual base salary of $975,000 (retroactive to her appointment as Inte
  • $4,355,000 — ong-term incentive award opportunity of $4,355,000. The Company has entered into a separ

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Separation and Release Agreement, dated as of March 22, 2024, by and between The Chemours Company and Mark E. Newman 99.1 Press Release, dated March 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CHEMOURS COMPANY Date: March 25, 2024 By: /s/ Matthew S. Abbott Name: Matthew S. Abbott Title: Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.